Title:Biologics in Inflammatory Immune-mediated Systemic Diseases
Volume: 18
Issue: 12
Author(s): Gianluca Moroncini*, Giovanni Calogera, Devis Benfaremo and Armando Gabrielli
Affiliation:
- Clinica Medica, Dipartimento di Scienze Cliniche e Molecolari, Universita Politecnica delle Marche, Ancona,Italy
Keywords:
ANCA-associated vasculitis, Behcet Disease, belimumab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic
Sclerosis (SSc), TNF-inhibitors, tocilizumab.
Abstract: Background: The use of biologic agents in systemic immune-mediated diseases has dramatically
increased in recent years, replacing conventional immunosuppressive strategies that are characterized
by unspecific mechanisms of action and burdened with serious adverse effects. Biologic drugs have
selective action towards specific targets, with considerable steroid-sparing effect. They are used nowadays
to induce remission or treat specific organ involvements in systemic autoimmune diseases.
Conclusion: In this review, we will discuss the scientific evidence supporting the use of biologics in
these diseases, with a particular emphasis on their efficacy and safety profile compared to the conventional
drugs.
